VERTEX PHARMACEUTICALS INC / MA
VRTXAPI behind this page
VRTX Q3 2025 request
Playground key active
/api/financials?ticker=VRTX&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 3,076.4 | 2,771.9 | +11.0% |
Show Product Lines breakouts |
|||
| ALYFTREK | 247 | — | — |
| CASGEVY | 16.9 | 2 | +745.0% |
| JOURNAVX | 19.6 | — | — |
| Manufactured Product Other | 175.8 | 186.9 | -5.9% |
| Product | 3,076.4 | 2,771.9 | +11.0% |
| Product · Accumulated Translation Adjustment | -39 | -3.1 | -1158.1% |
| Product · Europe | 836.9 | 847.7 | -1.3% |
| Product · Non Us | 1,100.1 | 1,058.4 | +3.9% |
| Product · Other | 263.2 | 210.7 | +24.9% |
| Product · US | 1,976.3 | 1,713.5 | +15.3% |
| TRIKAFTA/KAFTRIO | 2,653.6 | 2,585 | +2.7% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 3,076.4 | 2,771.9 | +11.0% |
| Cost of Revenue | 414.8 | 392.6 | +5.7% |
Show Product Lines breakouts |
|||
| Product · Pharmaceuticals | 139.6 | 131.6 | +6.1% |
| Royalty · Pharmaceuticals | 275.2 | 261 | +5.4% |
Show Collaborative Arrangements by Agreement [Axis] breakouts |
|||
| CRISPR JDCA | 43.3 | 15.8 | +174.1% |
| Research And Development Expense Excluding Acquired In Process Cost | 977.7 | 875.9 | +11.6% |
Show Collaborative Arrangements by Agreement [Axis] breakouts |
|||
| CRISPR JDCA | 14.3 | 11.7 | +22.2% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 54.5 | 15 | +263.3% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 54.5 | 15 | +263.3% |
| Selling, General & Administrative | 445.1 | 371.8 | +19.7% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -1.9 | 0.3 | -733.3% |
| Total Costs & Expenses | 1,890.2 | 1,655.6 | +14.2% |
| Operating Income | 1,186.2 | 1,116.3 | +6.3% |
| Investment Income Interest And Dividend | 125.7 | 132.2 | -4.9% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 125.7 | 132.2 | -4.9% |
| Interest Expense | -3.3 | -7.5 | +56.0% |
| Other Non-Operating Income (Expense) | -9.8 | -16.9 | +42.0% |
Show Equity Components breakouts |
|||
| Accumulated Translation Adjustment · Foreign Exchange Forward | -22.9 | 0.1 | -23000.0% |
| Income Before Taxes | 1,298.8 | 1,224.1 | +6.1% |
| Income Tax Expense (Benefit) | 215.9 | 178.7 | +20.8% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 215.9 | 178.7 | +20.8% |
| Net Income | 1,082.9 | 1,045.4 | +3.6% |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 1,082.9 | 1,045.4 | +3.6% |
Show Equity Components breakouts |
|||
| Retained Earnings | 1,082.9 | 1,045.4 | +3.6% |
| EPS (Basic) | 4.24 | 4.05 | +4.7% |
| EPS (Diluted) | 4.2 | 4.01 | +4.7% |
| Wtd Avg Shares (Basic) | 255.6 | 258 | -0.9% |
| Wtd Avg Shares (Diluted) | 257.6 | 261 | -1.3% |
| General & Administrative (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Pharmaceuticals | 166.8 | 154.9 | +7.7% |
| Comprehensive Income | 1,119.5 | 1,051.7 | +6.4% |
| Other Comprehensive Income | 36.6 | 6.3 | +481.0% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 36.6 | 6.3 | +481.0% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 4,939.6 | 5,239.2 | -5.7% |
| Marketable Securities (Current) | 1,347.4 | 1,285.3 | +4.8% |
| Accounts Receivable | 1,946.4 | 1,750.6 | +11.2% |
| Inventory | 1,626.8 | 1,079.8 | +50.7% |
| Prepaid Expenses & Other Current Assets | 709.4 | 449.2 | +57.9% |
| Total Current Assets | 10,569.6 | 9,804.1 | +7.8% |
| Non-Current Assets | |||
| Goodwill | 1,088 | 1,088 | 0.0% |
| Deferred Tax Assets | 2,937.2 | 2,308.9 | +27.2% |
| Operating Lease Right-of-Use Assets | 1,591.8 | — | — |
Show Lease Contractual Term breakouts |
|||
| Leiden II | 296.7 | — | — |
| Marketable Securities (Non-Current) | 5,722.8 | 4,703.5 | +21.7% |
| Other Non-Current Assets | 1,098 | 990.2 | +10.9% |
| Total Assets | 24,862.3 | 22,240.2 | +11.8% |
| Intangible Assets (Q) | — | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Employment Contracts | 4.2 | — | — |
| Marketing Related Intangible Assets | 201 | — | — |
| Other Assets | |||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 1,425.1 | 1,117.8 | +27.5% |
| Intangible Assets Net Excluding Goodwill | 429.8 | — | — |
| Current Liabilities | |||
| Accounts Payable | 420.3 | 395.8 | +6.2% |
| Accrued Liabilities | 3,613.5 | 3,219.7 | +12.2% |
| Other Liabilities Current | 441.5 | 357.6 | +23.5% |
| Total Current Liabilities | 4,475.3 | 3,973.1 | +12.6% |
| Non-Current Liabilities | |||
| Operating Lease Liabilities | 1,834.8 | — | — |
Show Lease Contractual Term breakouts |
|||
| Leiden II | 296.7 | — | — |
| Other Non-Current Liabilities | 1,233.4 | 933.3 | +32.2% |
| Total Liabilities | 7,543.5 | 6,609.3 | +14.1% |
| Stockholders' Equity | |||
| Common Stock | 2.5 | 2.6 | -3.8% |
| Additional Paid In Capital Common Stock | 5,011.9 | 6,905.7 | -27.4% |
| Accumulated Other Comprehensive Income | -64.5 | 28.8 | -324.0% |
| Retained Earnings | 12,368.9 | 8,693.8 | +42.3% |
| Total Stockholders' Equity | 17,318.8 | 15,630.9 | +10.8% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -137.7 | -31.7 | -334.4% |
| Accumulated Net Unrealized Investment Gain Loss | 34.5 | 51.2 | -32.6% |
| Accumulated Other Comprehensive Income | -64.5 | 28.8 | -324.0% |
| Accumulated Translation Adjustment | 38.7 | 9.3 | +316.1% |
| Additional Paid In Capital | 5,011.9 | 6,905.7 | -27.4% |
| Common Stock | 2.5 | 2.6 | -3.8% |
| Retained Earnings | 12,368.9 | 8,693.8 | +42.3% |
| Total Liabilities & Equity | 24,862.3 | 22,240.2 | +11.8% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation | 528.3 | 530.7 | -0.5% |
| Depreciation & Amortization | 154.1 | 160.7 | -4.1% |
| Increase Decrease In Other Deferred Liability | -541.3 | -400.4 | -35.2% |
| Equity Securities Fv Ni Unrealized Gain Loss | 12.2 | 50.5 | -75.8% |
| Other Non-Cash Items | 90.3 | -15.5 | +682.6% |
| Change in Accounts Receivable | -247.9 | -168.3 | -47.3% |
| Change in Inventory | -446.8 | -369.8 | -20.8% |
| Change in Prepaid & Other Assets | -145.4 | -35.7 | -307.3% |
| Change in Accounts Payable | -1.5 | 41.1 | -103.6% |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | 547.6 | 533 | +2.7% |
| Increase Decrease In Other Operating Liabilities | 42.7 | 45.1 | -5.3% |
| Net Cash from Operations | 3,133.4 | -1,077.2 | +390.9% |
| Investing Activities | |||
| Purchases of Investments | -5,165.9 | -5,279.6 | +2.2% |
| Proceeds From Sale And Maturity Of Available For Sale Securities | 4,805.6 | 3,005.4 | +59.9% |
| Capital Expenditures | -288.2 | -205.1 | -40.5% |
| Other Investing Activities | -8.8 | -23.1 | +61.9% |
| Net Cash from Investing | -657.3 | -2,948.1 | +77.7% |
| Financing Activities | |||
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 73.7 | 80.3 | -8.2% |
| Share Repurchases | -1,889 | -759.2 | -148.8% |
| Tax Withholding for Share Compensation | -367.4 | -397.7 | +7.6% |
| Finance Lease Principal Payments | -4 | -32.3 | +87.6% |
| Proceeds From Payments For Other Financing Activities | 2.6 | 5.3 | -50.9% |
| Net Cash from Financing | -2,184.1 | -1,103.6 | -97.9% |
| Supplemental | |||
| Income Taxes Paid | 1,177.3 | 810.3 | +45.3% |
| Interest Paid | 9.4 | 27.8 | -66.2% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 83.6 | 4.7 | +1678.7% |
| Net Change in Cash | 375.6 | -5,124.2 | +107.3% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 4,947.8 | 5,248.1 | -5.7% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.